Clinical Trials in Maastricht, Limburg

101 recruiting

Showing 120 of 99 trials

Recruiting
Phase 3

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Multiple Myeloma
Pfizer492 enrolled273 locationsNCT06152575
Recruiting
Phase 3

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

Prostate CancerProstatic Neoplasms
Merck Sharp & Dohme LLC1,440 enrolled286 locationsNCT06925737
Recruiting
Phase 2

A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants

Intraventricular hemorrhageChronic lung disease of prematurityBronchopulmonary Dysplasia+1 more
OHB Neonatology Ltd.338 enrolled72 locationsNCT03253263
Recruiting
Phase 3

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer
AbbVie698 enrolled317 locationsNCT04928846
Recruiting
Phase 2

Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER

Endometrial Cancer
Canadian Cancer Trials Group393 enrolled110 locationsNCT05640999
Recruiting
Phase 3

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

Breast Neoplasms
Merck Sharp & Dohme LLC1,200 enrolled259 locationsNCT06312176
Recruiting
Phase 3

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

Relapsed or Refractory Multiple Myeloma (RRMM)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company440 enrolled140 locationsNCT06615479
Recruiting
Not Applicable

The Effect of taVNS and Upper GI Motility

healthy adult participants
Daniel Keszthelyi12 enrolled1 locationNCT07632378
Recruiting
Phase 4

Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer

Prostate Cancer
Novartis Pharmaceuticals700 enrolled54 locationsNCT05803941
Recruiting
Not Applicable

Exploring the Role of taVNS in Nausea Management

healthy adult participants
Daniel Keszthelyi35 enrolled1 locationNCT07632456
Recruiting
Phase 2

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma
Genmab496 enrolled76 locationsNCT05283720
Recruiting
Phase 3

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

Carcinoma, Non-Small Cell Lung
Mirati Therapeutics Inc.630 enrolled353 locationsNCT06875310
Recruiting
Phase 3

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

Endometrial Cancer
Merck Sharp & Dohme LLC1,123 enrolled253 locationsNCT06952504
Recruiting
Phase 2

A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation

Atrial Fibrillation
Novartis Pharmaceuticals165 enrolled38 locationsNCT07217067
Recruiting
Phase 3

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

Carcinoma, Non-Small Cell Lung
Merck Sharp & Dohme LLC680 enrolled232 locationsNCT06623422
Recruiting
Not Applicable

Clinical Impact of Using IMPROVE to Select Patients for Carotid Revascularisation

Stroke, IschemicStrokeStroke (CVA) or TIA+7 more
Maastricht University Medical Center613 enrolled10 locationsNCT07556887
Recruiting
Phase 2Phase 3

A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

Pancreatic Ductal Adenocarcinoma
Bristol-Myers Squibb470 enrolled279 locationsNCT07076121
Recruiting

Bleeding Disorder of Unknown Cause in the Netherlands

Hemorrhagic DisordersBleeding Disorder of Unknown Cause
Maastricht University Medical Center500 enrolled8 locationsNCT07454161
Recruiting
Not Applicable

Amino Acid Oxidation of Whole-Food Protein: a Dose-Response Crossover Trial in Young Adults

Protein metabolism
Maastricht University Medical Center20 enrolled1 locationNCT07547176
Recruiting

Lab Research Using Mini-tumors to Study Prostate Cancer Treatments

Prostate CancerAdvanced Prostate CancerProstate Cancer Metastatic Disease+1 more
Maastricht Radiation Oncology600 enrolled3 locationsNCT07004582